StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 0.7 %

Shares of CPIX opened at $1.49 on Friday. The stock has a market capitalization of $21.14 million, a P/E ratio of -2.53 and a beta of 0.23. Cumberland Pharmaceuticals has a twelve month low of $1.38 and a twelve month high of $2.36. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $1.73.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The firm had revenue of $8.50 million for the quarter.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.